Buerger's Disease Clinical Trial
Official title:
Safety and Efficacy of Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Buerger's Disease
The purpose of this study is to investigate the efficacy and safety of autologous transplantation of Adipose Tissue derived Mesenchymal stem cells (MSCs) in patient with Buerger's disease.
Buerger's disease, also known as thromboangiitis obliterans, is a rare disorder that, in most
cases, affects young or middle-aged male cigarette smokers. It is characterized by narrowing
or blockage (occlusion) of the veins and arteries of the extremities, resulting in reduced
blood flow to these areas (peripheral vascular disease). The exact cause of Buerger's disease
is not known; however, most affected individuals are heavy tobacco users.
This drug is an autologous cell treatment for necrosis in the legs of patients with Beurger's
diseases to improve symptoms through vascular regeneration.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT01446055 -
Safety and Efficacy Study of Autologous BM-MNC Processed by Two Methods for Treating Patients With Chronic Limb Ischemia
|
Phase 1/Phase 2 | |
| Completed |
NCT01484574 -
A Clinical Trial to Study the Efficacy and Safety of Different Doses of Bone Marrow Derived Mesenchymal Stem Cells in Patients With Critical Limb Ischemia Due to Buergers Disease
|
Phase 2 | |
| Recruiting |
NCT05854615 -
Efficacy and Safety of Stempeucel® in Patients With Critical Limb Ischemia (CLI) Due to Buerger's Disease
|
Phase 4 |